BioSpace News Archive

Business

CraniUS Appoints World Leading Neurosurgeon to Join Board of Directors

CraniUS LLC, an R&D company focused on building groundbreaking diagnostics and treatments for patients with chronic brain disease, announced today the appointment of Henry Brem, MD to its accomplished Board of Directors.

November 15, 2022
·
3 min read
Drug Development

Cerevance Announces Presentation of Preclinical Study Results at the Society for Neuroscience Conference

Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, announced the presentation of preclinical study results during the poster session held November 14th at the Society for Neuroscience (SFN) 2022 conference in San Diego, California.

November 15, 2022
·
2 min read
Biotech Bay

Pliant Therapeutics to Participate in Upcoming November 2022 Investor Conferences

Pliant Therapeutics, Inc., a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, announced participation in the following November investor conferences:

November 15, 2022
·
2 min read
Drug Development

AUM Biosciences Receives Human Research Ethics Committee Approval to Commence Phase II Clinical Trial of AUM001 for Treatment of Metastatic Colorectal Cancer in Australia

AUM Biosciences Pte. Ltd. today announced it has received Human Research Ethics Committee (“HREC”) approval to commence a Phase II clinical trial of its selective translation inhibitor AUM001 in Australia.

November 15, 2022
·
11 min read
FDA

Apollomics Inc. Receives FDA Orphan Drug Designation for Vebreltinib (APL-101) for Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor Aberrations

Apollomics Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to vebreltinib (APL-101) for the treatment of non-small cell lung cancer (NSCLC) with MET genomic tumor aberrations.

November 15, 2022
·
15 min read
Business

Vyant Bio Reports Third Quarter 2022 Results and Provides Strategic and Business Highlights

Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. Today, Vyant Bio announces results for the third quarter of 2022.

November 15, 2022
·
13 min read
Island to present at World Antiviral Congress 2022

Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd is pleased to advise that CEO and Managing Director, Dr David Foster will present at the World Antiviral Congress 2022 in San Diego, USA which runs from 28 November – 1 December 2022.

November 15, 2022
·
2 min read
BioMidwest

NorthStar Medical Radioisotopes Expands Business Platform with New, Patient-focused, Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) Services Unit

NorthStar Medical Radioisotopes, LLC announced a significant expansion of its business platform with the formation of a new, patient-focused Radiopharmaceutical Contract Development and Manufacturing Organization services unit.

November 15, 2022
·
6 min read
Biotech Beach

Boundless Bio to Participate at Two Upcoming Investor Conferences

Boundless Bio today announced that its Chief Executive Officer, Zachary Hornby, will participate in a presentation and fireside chat at upcoming investor conferences.

November 15, 2022
·
1 min read
Pharm Country

Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference

Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Stifel 2022 Healthcare Conference in New York, NY on Wednesday, November 16, 2022 at 9:45 a.m. E.T.

November 15, 2022
·
1 min read